Merck

Pindolol augmentation of antidepressant therapy.

The British journal of psychiatry : the journal of mental science (1999-02-02)
R McAskill, S Mir, D Taylor
ABSTRACT

Antidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmentor of antidepressant response. A Medline search was conducted in November 1997. Six open-label studies and six controlled studies were identified for review. Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit. Larger, well-designed, controlled trials are needed to determine definitively the effectiveness of pindolol in this context.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pindolol, ≥98% (TLC), powder
Pindolol, European Pharmacopoeia (EP) Reference Standard